Scopolamine

Summary

Scopolamine (CHEMBL569713) is an approved small-molecule muscarinic antagonist (ATC S01FA02) targeting CHRM1, CHRM2, and CHRM3; indicated across 14 conditions including motion sickness and major depressive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01FA02 (+3 more)
• Targets: 5 (CHRM1, CHRM2, CHRM3…)
• Indications: 14 conditions
• Clinical trials: 47
• Chemistry: 303.35 Da · C17H21NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL569713
Name	Scopolamine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3000322
ChEBI	CHEBI:16794
ATC	S01FA02, A04AD01, A04AD51, N05CM05
Molecular formula	C17H21NO4
Molecular weight	303.35
InChIKey	STECJAGHUSJQJN-USLFZFAMSA-N

SMILES: CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4

IUPAC name: [(1S,2S,4R,5R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate

ChEBI definition: A tropane alkaloid that is the (S)-tropic acid ester of 6β,7β-epoxy-1αH,5αH-tropan-3α-ol.

Pharmacological roles (ChEBI): muscarinic antagonist, antiemetic, adjuvant, mydriatic agent, antispasmodic drug, anaesthesia adjuvant, antidepressant.

Other ChEBI roles (chemical / environmental): metabolite.

Also known as: Scopolamine, Transderm scop, hyoscine, scopolamine, SCOPOLAMINE, buscopan, SCOPOLINE, (-)-SCOPOLAMINE HYDROBROMIDE

Parent form; salt/anhydrous children: CHEMBL1530287, CHEMBL1877254, CHEMBL2251240, CHEMBL3185877

Patent coverage: 17,727 distinct patent families (49,484 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CHRM1	M1 receptor	Antagonist	9	0.2%	P11229
CHRM2	M2 receptor	Antagonist	8.7	0%	P08172
CHRM3	M3 receptor	Antagonist	9.4	0%	P20309
CHRM4	M4 receptor	Antagonist	9.5	1.6%	P08173
CHRM5	M5 receptor	Antagonist	8.7	0%	P08912

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Muscarinic acetylcholine receptor M4, Muscarinic acetylcholine receptor, Muscarinic acetylcholine receptor M5, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M3, Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3.

Bioactivity

ChEMBL activities: 39 potent at pChembl ≥ 5 of 40 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P08482	10.1	Ki	0.08	nM	CHEMBL_ACT_1063087
P08482	9.28	Ki	0.53	nM	CHEMBL_ACT_74990
P08483	9.19	Kd	0.65	nM	CHEMBL_ACT_550606
CHRM2	9.15	AC50	0.7	nM	CHEMBL_ACT_25196401
P08482	9.12	Kd	0.75	nM	CHEMBL_ACT_550603
CHRM2	8.92	AC50	1.2	nM	CHEMBL_ACT_25214350
CHRM5	8.89	Ki	1.29	nM	CHEMBL_ACT_15059787
CHRM4	8.89	IC50	1.29	nM	CHEMBL_ACT_15087524
CHRM1	8.82	AC50	1.5	nM	CHEMBL_ACT_25210707
CHRM1	8.77	AC50	1.7	nM	CHEMBL_ACT_25210786
CHRM1	8.76	IC50	1.74	nM	CHEMBL_ACT_15087338
CHRM1	8.73	IC50	1.85	nM	CHEMBL_ACT_25974900
CHRM3	8.72	AC50	1.9	nM	CHEMBL_ACT_25137302
CHRM1	8.57	AC50	2.7	nM	CHEMBL_ACT_25136103
CHRM2	8.52	Ki	3.02	nM	CHEMBL_ACT_15056231
CHRM1	8.52	AC50	3	nM	CHEMBL_ACT_25210706
P10980	8.52	Kd	3	nM	CHEMBL_ACT_550605
CHRM2	8.48	Ki	3.31	nM	CHEMBL_ACT_15059742
CHRM2	8.48	Ki	3.31	nM	CHEMBL_ACT_15059772
CHRM1	8.48	IC50	3.31	nM	CHEMBL_ACT_15087415
CHRM2	8.45	Ki	3.55	nM	CHEMBL_ACT_15059757
CHRM4	8.42	IC50	3.8	nM	CHEMBL_ACT_15087452
CHRM4	8.42	IC50	3.8	nM	CHEMBL_ACT_15087489
P08482	8.4	IC50	4	nM	CHEMBL_ACT_515148
P08482	8.4	IC50	4	nM	CHEMBL_ACT_515149
CHRM1	8.36	IC50	4.37	nM	CHEMBL_ACT_15087376
P10980	8.34	Ki	4.57	nM	CHEMBL_ACT_74991
CHRM3	8.19	Ki	6.5	nM	CHEMBL_ACT_12627790
CHRM1	8.12	Ki	7.5	nM	CHEMBL_ACT_12629800
CHRM3	8.1	AC50	7.9	nM	CHEMBL_ACT_25137304
CHRM2	8.08	AC50	8.4	nM	CHEMBL_ACT_25196306
CHRM2	8.02	Ki	9.5	nM	CHEMBL_ACT_12627799
P08482	8	IC50	10	nM	CHEMBL_ACT_355179
CHRM1	7.9	AC50	12.5	nM	CHEMBL_ACT_25136105
CHRM5	7.75	Ki	17.6	nM	CHEMBL_ACT_12627964
CHRM2	7.7	AC50	20	nM	CHEMBL_ACT_25214352
CHRM2	7.54	Ki	28.84	nM	CHEMBL_ACT_15056247
CHRM4	7.43	Ki	36.9	nM	CHEMBL_ACT_12627781
CHRM2	7.41	AC50	39.2	nM	CHEMBL_ACT_25195412

Target pathways

Aggregated over 5 target gene(s): CHRM1, CHRM2, CHRM3, CHRM4, CHRM5.

Top Reactome pathways

17 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Signaling by GPCR	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Class A/1 (Rhodopsin-like receptors)	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Amine ligand-binding receptors	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
GPCR downstream signalling	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Muscarinic acetylcholine receptors	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
GPCR ligand binding	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
G alpha (q) signalling events	3	CHRM1, CHRM3, CHRM5
G alpha (i) signalling events	2	CHRM2, CHRM4
Metabolism	1	CHRM3
Integration of energy metabolism	1	CHRM3
Membrane Trafficking	1	CHRM2
Acetylcholine regulates insulin secretion	1	CHRM3
Regulation of insulin secretion	1	CHRM3
Vesicle-mediated transport	1	CHRM2
Cargo recognition for clathrin-mediated endocytosis	1	CHRM2
Clathrin-mediated endocytosis	1	CHRM2

Dominant GO biological processes

GO term	Targets
signal transduction	5
G protein-coupled receptor signaling pathway	5
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	5
G protein-coupled acetylcholine receptor signaling pathway	5
chemical synaptic transmission	5
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	3
nervous system development	3
acetylcholine receptor signaling pathway	3
regulation of locomotion	2
saliva secretion	2
regulation of smooth muscle contraction	2
phospholipase C-activating G protein-coupled receptor signaling pathway	1
neuromuscular synaptic transmission	1
positive regulation of monoatomic ion transport	1

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
motion sickness	4	MONDO:0008015	EFO:0006928

7 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
major depressive disorder	2	MONDO:0002009	MONDO:0002009
depressive disorder	2	MONDO:0002050	MONDO:0002050
amyotrophic lateral sclerosis	2	MONDO:0004976	MONDO:0004976
bipolar disorder	2	MONDO:0004985	MONDO:0004985
social phobia	1	MONDO:0001247	EFO:1001917
dementia	1	MONDO:0001627	HP:0000726
Alzheimer disease	1	MONDO:0004975	MONDO:0004975

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 47.

Phase distribution

Phase	Trials
Not specified	13
PHASE1	10
PHASE4	7
PHASE2	6
PHASE3	4
EARLY_PHASE1	4
PHASE2/PHASE3	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04240626	PHASE4	ACTIVE_NOT_RECRUITING	Multimodal Analgesia Effect on Post Surgical Patient
NCT02103166	PHASE4	SUSPENDED	Role of Hyoscine Bromide in Latent and Active Labor
NCT02960113	PHASE4	COMPLETED	Scopolamine Patch and Acupressure Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean Section
NCT02968082	PHASE4	UNKNOWN	The Effects of Preoperative Scopolamine Patch Application on the Postoperative Nausea and Vomiting in MVD Surgery
NCT03131050	PHASE4	COMPLETED	Effectiveness Study of Scopolamine Combined With Escitalopram in Patients With MDD
NCT03386448	PHASE4	COMPLETED	The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression
NCT03435003	PHASE4	COMPLETED	Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy
NCT05719467	PHASE3	RECRUITING	SAINT: Safe Induction of Labor Trial
NCT01644838	PHASE2/PHASE3	COMPLETED	Effect of Hyoscine and Promethazine on Labor Pain
NCT02155309	PHASE2/PHASE3	TERMINATED	Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray
NCT03920644	PHASE3	UNKNOWN	Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels
NCT03988530	PHASE3	COMPLETED	Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects
NCT04272255	PHASE3	UNKNOWN	Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness
NCT00369915	PHASE2	TERMINATED	The Antidepressant Efficacy of the Anticholinergic Scopolamine
NCT00374478	PHASE2	COMPLETED	Effects of Transdermal Scopolamine on Occupational Performance
NCT01312844	PHASE2	TERMINATED	A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)
NCT02557087	PHASE2	UNKNOWN	Hyoscine ButylBromide for Intrapartum Analgesia
NCT02613494	PHASE1/PHASE2	COMPLETED	Clozapine-induced Hypersalivation - Feasibility Trial
NCT04211961	PHASE2	COMPLETED	Scopolamine in Bipolar Depression
NCT04666701	PHASE2	WITHDRAWN	Efficacy and Safety of Escócia Association in the Treatment of Acute Pain
NCT00646061	PHASE1	COMPLETED	Pain Control in Renal Colic
NCT01213355	PHASE1	COMPLETED	Scopolamine Challenge Study
NCT01345864	PHASE1	TERMINATED	Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults
NCT01900301	PHASE1	COMPLETED	Generalization of Extinction Learning
NCT02051335	PHASE1	COMPLETED	Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults
NCT02918266	PHASE1	TERMINATED	TAK-071 Scopolamine-Induced Cognitive Impairment Study
NCT03030105	PHASE1	COMPLETED	Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers
NCT03874130	PHASE1	UNKNOWN	Scopolamine in Healthy Volunteers
NCT04999449	PHASE1	COMPLETED	Nebulizer Delivery of Intranasal Scopolamine
NCT06014385	PHASE1	WITHDRAWN	PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor
NCT04366518	EARLY_PHASE1	RECRUITING	Toward a Computationally-Informed, Personalized Treatment for Hallucinations
NCT05594017	EARLY_PHASE1	RECRUITING	Pharmacological Modulation of Brain Oscillations in Memory Processing
NCT07423923	EARLY_PHASE1	ENROLLING_BY_INVITATION	Representation of Spatiotemporal Information in Human Episodic Memory and Navigation
NCT02849639	EARLY_PHASE1	COMPLETED	The INCREASE Study - Delaying the Onset of Alzheimer’s Symptomatic Expression
NCT04751084	Not specified	ACTIVE_NOT_RECRUITING	Buscopan in Patients Undergoing IVF/Intracytoplasmic Sperm Injection Treatment
NCT07523997	Not specified	RECRUITING	Imaging of Endometriosis With Total-body PET-CT (PET-Endo)
NCT00659737	Not specified	COMPLETED	Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting
NCT00717054	Not specified	COMPLETED	Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting
NCT01198106	Not specified	UNKNOWN	A Double-blind Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness
NCT01379001	Not specified	COMPLETED	Assessment of Cholinergic and Cognitive Function Using Pharmacologic ASL-Perfusion MRI
NCT01613820	Not specified	WITHDRAWN	Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder
NCT02273895	Not specified	COMPLETED	The Use of EEG in Alzheimer’s Disease, With and Without Scopolamine - A Pilot Study
NCT02410460	Not specified	COMPLETED	Anesthetics in Rhytidoplasty - A Comparison Study
NCT02625181	Not specified	COMPLETED	Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis
NCT02725398	Not specified	UNKNOWN	Effect of Buscopan on Gastrointestinal Imaging Quality With Probe-based Confocal Laser Endomicroscopy
NCT02910167	Not specified	COMPLETED	Observational Prospective Study to Evaluate AEs, Risk Factors and Drug Utilization of BUSCAPINA COMPOSITUM N in Adults From Metropolitan Lima
NCT04866355	Not specified	COMPLETED	Lumbar Spine Manipulation Versus Pharmacological Therapy in Young Women With Primary Dysmenorrhea

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

576 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
ACLIDINIUM BROMIDE	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CLOZAPINE	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Mavorixafor	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
OLANZAPINE	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
ACETYLCHOLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
AMIODARONE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
AMOXAPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
ATROPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
BENZTROPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
BETHANECHOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CARBACHOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CARBAMOYLCHOLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CHLOROQUINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CINNARIZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CLEMASTINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CLIDINIUM	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CYCLIZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DARIFENACIN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DESLORATADINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DEXCHLORPHENIRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DICYCLOMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DIMENHYDRINATE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DIPHENIDOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DOXEPIN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
EBASTINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
GLYCOPYRRONIUM BROMIDE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
HALOPERIDOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
HOMATROPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
HYDROXYCHLOROQUINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
IMIPRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
IPRATROPIUM	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
KETOTIFEN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
LOXAPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
MAPROTILINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
MEPAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
METHSCOPOLAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
METHSCOPOLAMINE BROMIDE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
MIANSERIN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
ORPHENADRINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
OXYBUTYNIN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PAROXETINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PERHEXILINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PILOCARPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PIRENZEPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PROCHLORPERAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PROMAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PROMETHAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
QUETIAPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
QUINACRINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
RISPERIDONE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
SERTRALINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
SOLIFENACIN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
SULOCTIDIL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
TAMOXIFEN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
TERCONAZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
THIORIDAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
TIOTROPIUM BROMIDE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
TOLTERODINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
TRIHEXYPHENIDYL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
TROPICAMIDE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
TROSPIUM CHLORIDE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
XANOMELINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DIMETHINDENE	ChEMBL	Phase 3	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
ENCLOMIPHENE	ChEMBL	Phase 3	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
ABAPERIDONE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
APROFENE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
BENZETHONIUM CHLORIDE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
FLUNARIZINE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PF-03635659	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
SABCOMELINE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
TALSACLIDINE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
BETAMETHASONE PHOSPHORIC ACID	ChEMBL	Phase 4 (approved)	CHRM1, CHRM3, CHRM4, CHRM5
BIPERIDEN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
CARIPRAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM4, CHRM5
CEVIMELINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
ECONAZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
FLUOXETINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM5
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
MICONAZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
OXYMETAZOLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM4, CHRM5
SULCONAZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM3, CHRM4, CHRM5
BLARCAMESINE	ChEMBL	Phase 3	CHRM1, CHRM2, CHRM3, CHRM4
METHYLBENACTYZIUM BROMIDE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4
OTENZEPAD	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4
ZOTEPINE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4
Afatinib	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3
chenodiol	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3
LINAGLIPTIN	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3
Propoxyphene	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3
ACETYLCHOLINE CHLORIDE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM3, CHRM5
AMBENONIUM	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3